The Rise of First in Class Drugs: What the latest clinical data

The Rise of First in Class Drugs: What the latest clinical data

Introduction

In a significant paradigm shift in the pharmaceutical industry, new drugs are being developed that represent “first in class” medications, which have brand new mechanisms of action for treatment of diseases. These are not incremental or follow-on drugs, but the latest in biological understanding and changing the way the modern clinical drug development process should be done.

In recent years, the FDA has approved new products and clinical studies that are clearly signaling a shift towards innovation-incentivized Research and Development. The FDA has approved 37 new drugs in 2022, which represents more than half of the first in class approvals. This is in line with the general trend in the pharmaceutical industry, as companies shift from incremental changes towards novel targets.

The transition is also impacting the way the clinical drug development process works, shifting to more of a data-driven, biomarker-centric and adaptive process, as well as introduces greater scientific and regulatory complexity.

What does the term ‘First in Class Drug' mean?

Drugs with a novel mechanism of action (MoA) to treat a disease are first in class drugs. They are also the first treatments to be approved for a previously unexploited biological pathway.

Unlike:

• Drugs that are best in class to address the need for improvement in existing treatments
• Follow-on drugs that mimic active drugs

The first-in-class therapies create completely new therapeutic categories.

They are extremely useful in the clinical drug development process as they are generally drugs that go straight to the market to meet unmet medical needs but they are also riskier because they are not thoroughly validated biologically before entering human trials.

Understanding the Role of These in the Clinical Drug Development Process

First-in-class drugs go through the typical clinical stages, but with much greater uncertainty:

• Phase I: Focus on safety and early biological activity, with unknown risk profiles.
• Phase II: Essential to confirm if the new mechanism can function in humans
• Phase III: Confirms efficacy using adaptive or biomarker-driven designs

As opposed to conventional drugs, this clinical drug development process is not linear, but rather flexible and iterative. The study design is frequently changed during development, due to biomarkers, adaptive trials and real-time data.

What Latest Clinical Data Shows

- Clinical and Regulatory data points to robust first in class innovation:

• A steady stream of novel therapies has been constantly identified with FDA approvals, and high percentages of first in class have been consistently identified.
• Tumors will remain the leading class of drug targets as there has been progress in tumor biology and in immunotherapies.Advances in tumor biology and immunotherapy will sustain overall progress in Oncology, the area that will continue to maintain its position as the primary therapeutic area.
• Rare diseases and immunology make significant contributions to innovation as well.
• Biomarker-based trials become the norm in early phases of development

The trends reflect a transition towards precision medicine in clinical drug development, with patient selection and molecular profiling playing a key role in successful development.

Why First-in-Class Drugs Are More Challenging

As the name suggests, ‘first-in-class' drugs are more difficult.The name ‘first-in-class' says it all: they're harder to do.

Key challenges include:

• Biological uncertainty: Targets may not act as they are supposed to do in humans
• High Phase II failure rates: Efficacy signals are weak or not consistent
• Complex trial design: Needs adaptive and biomarker approaches
• Regulatory complexity: Few precedents for new mechanisms

While the FDA and other regulators may provide expedient routes, they still need robust evidence generation strategies in the clinical drug development process.

What Is Driving Their Rise?

So what makes them so popular that they're rising?

The first-class innovation space is being driven by several forces:

1. Genomics and Target Discovery

Newly discovered disease mechanisms through advanced sequencing and molecular biology techniques.

2. Precision Medicine

The use of biomarkers enables patient-specific treatment approaches leading to higher efficiency and success rates for trials.

3. Artificial Intelligence

AI helps to identify novel drug targets and predict the clinical outcomes, which comes with the ability to speed up the process.

4. Pharma Strategy Shift

While companies are shifting away from incremental drugs in response to the barriers of pricing and competition, they are increasingly turning more to the high-value, differentiated ones.

These forces are driving the clinical drug development process to become more predictive and data-driven.

How clinical data is evolving development?

The evolution of clinical data in the development.

Clinical data has become key to the decision-making in the first in class drug programs.

Modern development relies on:

• Early detection of signals in phase I/II trials,
• Biomarker-driven patient selection
• Adaptive trial modifications based on interim results.
• Simultaneously, to predict the probability of success in a project, he is capable of predictive modeling.

Real-world evidence has also become more of a part of the picture, providing insights that are beyond those provided in clinical trials and building regulatory confidence.

This results in a more continuous clinical drug development process with decision making reflecting real-world evidence as it is generated.

Future Outlook

The next 10 years of drug development will be characterized by:

Cell and Gene Therapies

Providing possibly curative treatment but with long term monitoring for safety.

RNA-Based Drugs

Accelerating and facilitating rapid therapeutic advances for rare and common diseases.

AI-Driven Drug Discovery

Finding new mechanisms, and speeding up development timelines.

Biomarker-First Development

Identifying patient population prior to trial design, enhancing precision and efficiency.

Real-World Evidence Integration

Helping to inform regulatory decisions and to expand clinical insights after trials.

All these trends will contribute to making clinical drug development more connected, responsive and smarter.

Conclusion

First-in-class drugs are changing the pharmaceutical landscape by pushing innovation beyond the smallest of steps to real biological breakthroughs. They're altering the clinical drug development process to be more data-driven, adaptive, and precision.

With these therapies will be increased scientific and regulatory risk, but also the greatest potential for transformative impact in medicine.

Genomics, AI and real world evidence are intertwining and first-in-class drugs will become a bigger part of the future of global drug development and therapeutic innovation.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!